Study of the Effect of Different Hepatitis C Virus Genotypes on Splenomegaly.
genotypes
hcv
splenomegaly
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
31 Aug 2020
31 Aug 2020
Historique:
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
Background Several recent studies have shown that the hepatitis C virus (HCV) and its different genotypes are a predominant and leading cause of cirrhosis and splenomegaly in different regions of the world. Advanced stage of cirrhosis leads to portal hypertension that causes splenomegaly. This complication may have many other manifestations such as anemia, infections, and bleeding disorders in severe stages. This study aimed to determine the effect of different HCV genotypes on the development of splenomegaly and to assess which HCV genotypes are more associated with it. Materials and methods A total of 483 conveniently sampled HCV patients were included in this descriptive cross-sectional study. Six genotypes (1, 2a, 2b, 3a, 3b, and mixed) were studied, and 80 patients for each of these genotypes were included. Data were collected from patient medical records regarding patient demographic details, HCV serology and genotyping, and sonographic size of the spleen. Results In total, splenomegaly was present in 14.1% (n=68) patients. The development of splenomegaly was significantly associated with old age, as 25.2% (n=26) of patients above 60 years of age (n=103) developed splenomegaly (P=0.005). Our study determined that splenomegaly was significantly related to HCV genotypes 3a, 3b, and 1 (P<0.001, P=0.017, and P=0.019, respectively). By taking mixed genotype as a reference, the odds of developing splenomegaly with genotype 3a were the highest (OR = 9.481; CI=95%). Conclusions Our study concludes that HCV genotype 3a, 3b, and 1, and age above 60 years have a significant association with splenomegaly. Genotype 3a has the highest risk of developing splenomegaly. Therefore, our study demands screening, early diagnosis, and prompt treatment of these particular HCV genotypes to prevent complications and risk of mortality.
Identifiants
pubmed: 33014659
doi: 10.7759/cureus.10164
pmc: PMC7526956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10164Informations de copyright
Copyright © 2020, Azhar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Gastroenterol Hepatol. 2017 Jan;2(1):52-62
pubmed: 28404015
Liver Int. 2018 Feb;38 Suppl 1:14-20
pubmed: 29427491
Chin Med J (Engl). 2020 Feb 5;133(3):253-261
pubmed: 31934936
Euroasian J Hepatogastroenterol. 2020 Jan-Jun;10(1):7-10
pubmed: 32742965
Int J Mol Sci. 2017 Dec 22;19(1):
pubmed: 29271914
Indian J Med Res. 2018 May;147(5):445-455
pubmed: 30082568
J Med Virol. 2017 Nov;89(11):1973-1980
pubmed: 28671305
World J Gastroenterol. 2016 Jan 28;22(4):1684-700
pubmed: 26819533
Nat Rev Dis Primers. 2017 Mar 02;3:17006
pubmed: 28252637
PLoS One. 2019 Apr 3;14(4):e0214435
pubmed: 30943224
Braz J Infect Dis. 2020 Jul - Aug;24(4):304-309
pubmed: 32735876
Cells. 2019 Oct 14;8(10):
pubmed: 31615075
SAGE Open Med Case Rep. 2020 Jan 23;8:2050313X20901900
pubmed: 32047630
J Transl Med. 2017 May 23;15(1):111
pubmed: 28535799
Infect Dis Clin North Am. 2017 Dec;31(4):827-838
pubmed: 29079161
Curr Med Res Opin. 2017 May;33(5):829-836
pubmed: 28128648
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
World J Hepatol. 2015 Nov 18;7(26):2676-80
pubmed: 26609344